Bibliography
- Bermudez-Humaran LG. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin 2009;4:264-7
- Van Huynegem K, Loos M, Steidler L. Immunomodulation by genetically engineered lactic acid bacteria. Front Biosci 2009;14:4825-35
- Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008;5:349-62
- Iwaki M, Okahashi N, Takahashi I, Oral immunization with recombinant Streptococcus lactis carrying the Streptococcus mutans surface protein antigen gene. Infect Immun 1990;58:2929-34
- Mielcarek N, Alonso S, Locht C. Nasal vaccination using live bacterial vectors. Adv Drug Deliv Rev 2001;51:55-69
- Braat H, Rottiers P, Hommes DW, A Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4:754-9
- Steidler L, Neirynck S, Huyghebaert N, Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003;21:785-9
- Vandenbroucke K, de Haard H, Beirnaert E, Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2009;1:49-56
- Hanniffy SB, Carter AT, Hitchin E, Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 2007;195:185-93
- de Ruyter PG, Kuipers OP, de Vos WM. Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl Environ Microbiol 1996;62:3662-7
- Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004;53:427-33
- Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11:45-53
- Yewdell JW. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 2001;11:294-7
- Cuesta AM, Suarez E, Larsen M, Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I. Immunology 2006;117:502-6
- Chen CH, Wang TL, Hung CF, Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-42
- Kim JW, Hung CF, Juang J, Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 2004;11:1011-18
- Liao CW, Chen CA, Lee CN, Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 2005;65:9089-98
- Loera-Arias MJ, Martinez-Perez AG, Barrera-Hernandez A, Targeting and retention of HPV16 E7 to the endoplasmic reticulum enhances immune tumour protection. J Cell Mol Med 2010;14:890-4
- Hung CF, Monie A, Alvarez RD, DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 2007;39:679-89
- Lee P, Faubert GM. Expression of the Giardia lamblia cyst wall protein 2 in Lactococcus lactis. Microbiology 2006;152:1981-90
- Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005;175:7297-302
- Steidler L, Rottiers P, Coulie B. Actobiotics as a novel method for cytokine delivery. Ann NY Acad Sci 2009;1182:135-45
- Bosma T, Kanninga R, Neef J, Novel surface display system for proteins on non-genetically modified Gram-positive bacteria. Appl Environ Microbiol 2006;72:880-9
- van Roosmalen ML, Kanninga R, El Khattabi M, Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods 2006;38:144-9
- Zechini B, Cipriani P, Papadopoulou S, Endocarditis caused by Lactococcus lactis subsp. lactis in a patient with atrial myxoma: a case report. Diagn Microbiol Infect Dis 2006;56:325-8
- Pellizzer G, Benedetti P, Biavasco F, Bacterial endocarditis due to Lactococcus lactis subsp. cremoris: case report. Clin Microbiol Infect 1996;2:230-2
- Audouy SA, van Selm S, van Roosmalen ML, Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 2007;25:2497-506
- Mierau I, Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 2005;68:705-17
- Kang TH, Kim KW, Bae HC, Enhancement of DNA vaccine potency by antigen linkage to IFN-gamma-inducible protein-10. Int J Cancer 2010, doi: 10.1002/ijc.25391
- Fuglsang A. Lactic acid bacteria as prime candidates for codon optimization. Biochem Biophys Res Commun 2003;312:285-91
- Mijakovic I, Petranovic D, Jensen PR. Tunable promoters in systems biology. Curr Opin Biotechnol 2005;16:329-35